Cooper Companies heads into its September earnings with an unusual tension: options traders are near their most bullish in a year, while short interest has quietly rebuilt over the past week.
The options market tells the clearest story here. The put/call ratio has collapsed to 0.163 — nearly 1.4 standard deviations below its 20-day average of 0.39 — and is hovering just above its 52-week low of 0.161. That's an exceptionally call-heavy positioning relative to the recent norm, suggesting options traders are leaning hard into upside ahead of the September 3 print. What makes this notable is the contrast with where the PCR was sitting just two weeks ago: it ran above 0.50 through most of July, meaning the shift toward calls has been rapid and concentrated. The stock itself has backed up that move — COO gained 2.6% on the week to close at $76.17, and is up more than 11% over the past month.
Short interest, however, is moving in the opposite direction. Bears added positions aggressively this week — short interest climbed 11% week-on-week to 3.9% of the free float. That's a meaningful acceleration after a month where shorts had been gradually covering; the July peak was above 8.8 million shares, covering ran through early August, and the last few sessions saw that unwind reverse sharply. The borrow market gives shorts little friction for rebuilding: availability is running at roughly 1,558% — over 133 million shares available against roughly 7.8 million currently short — meaning there is no mechanical squeeze pressure. Cost to borrow remains negligible at 0.51%, barely changed on the week. The short score from ORTEX is stable near 37.6, sitting in the middle of its recent range and not flashing any unusual signal in either direction.
The Street is cautiously constructive but far from unanimous. Citigroup raised its target to $80 from $76 this week while keeping a Neutral rating, and UBS initiated with a Neutral and a $75 target at the end of July. The consensus mean sits at $81.50 — around 7% above the current price — but recent history shows analyst credibility took a hit after the June earnings print, when multiple firms (JPMorgan, Wells Fargo, Needham, Baird, Mizuho) all cut targets sharply from the $80–$101 range into the $66–$86 band. The bull case rests on CooperVision's 25% US contact lens share and CooperSurgical's dominance of the IVF cycle; the bear case centres on pricing power limits, APAC revenue headwinds, and a forward EPS picture that has lost upward momentum — EPS surprise ranks in just the 9th percentile of the universe and EPS momentum is below average. The EV/EBITDA at 12.6x has compressed modestly over 30 days, a gentle move in the right direction for value-focused buyers, but the valuation is not yet cheap enough to act as a standalone catalyst.
One institutional holder worth noting is Browning West, a known activist-oriented fund, which had built to 3.6% of shares — a 3.3 million share addition as of the March 31 filing. That filing is now dated, but the position size matters as context: an activist presence in the register alongside the emerging call-heavy options positioning creates a setup where any positive catalyst could draw faster-than-usual institutional response.
The June earnings release — COO's most recent print — produced an 11.6% one-day gain and held a 11.9% five-day advance. Peers have been generally positive on the week: MDT added 4.7%, RMD gained 5.9%, and BDX rose 3.7%, suggesting broader medical device sentiment is supportive heading into the next reporting cycle.
With the September 3 earnings date approaching, the gap between a call-skewed options market and a freshly rebuilt short base is the dynamic worth tracking — specifically whether short interest continues climbing into the release or whether it fades again as it did through late July.
See the live data behind this article on ORTEX.
Open COO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
